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Background: To determine if tuberculosis (TB) screening improves patient outcomes, we conducted two sys-
tematic reviews to investigate the effect of TB screening on diagnosis, treatment outcomes, deaths (clinical
review assessing 23 outcome indicators); and patient costs (economic review).
Methods: Pubmed, EMBASE, Scopus and the Cochrane Library were searched between 1/1/1980-13/4/2020
(clinical review) and 1/1/2010-14/8/2020 (economic review). As studies were heterogeneous, data synthesis
was narrative.
Findings: Clinical review: of 27,270 articles, 18 (n=3 trials) were eligible. Nine involved general populations.
Compared to passive case finding (PCF), studies showed lower smear grade (n=2/3) and time to diagnosis
(n=2/3); higher pre-treatment losses to follow-up (screened 23% and 29% vs PCF 15% and 14%; n=2/2); and
similar treatment success (range 68-81%; n=4) and case fatality (range 3-11%; n=5) in the screened group.
Nine reported on risk groups. Compared to PCF, studies showed lower smear positivity among those culture-
confirmed (n=3/4) and time to diagnosis (n=2/2); and similar (range 80-90%; n=2/2) treatment success in the
screened group. Case fatality was lower in n=2/3 observational studies; both reported on established screen-
ing programmes. A neonatal trial and post-hoc analysis of a household contacts trial found screening was
associated with lower all-cause mortality. Economic review: From 2841 articles, six observational studies
were eligible. Total costs (n=6) and catastrophic cost prevalence (n=4; range screened 9-45% vs PCF 12-61%)
was lower among those screened.
Interpretation:We found very limited patient outcome data. Collecting and reporting this data must be priori-
tised to inform policy and practice.
Funding:WHO and EDCTP.
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Despite effective, curative treatment, tuberculosis (TB) is a
leading infectious cause of death worldwide [1]. In most TB-
endemic settings, standard case-detection through routine serv-
ices (passive case-finding [PCF]), is the mainstay of access to TB
diagnosis and treatment [2,3]. This may be augmented by facility-
Research in context
Evidence before this study
Tuberculosis (TB) remains a leading infectious cause of death
worldwide, and therefore improving access to diagnosis and
treatment, closing the case-detection gap and improving
patient outcomes is a priority. In 2019, a MEDLINE and EMBASE
search for English language articles on TB screening identified a
systematic review. Synthesising data published between 1/1/
1980-13/10/2010, it found little evidence that TB screening
benefited individuals screened; patient costs were not assessed.
Added value of this study
Synthesising evidence between 1980-2020, our systematic
review investigating the effects of TB screening on patient out-
comes, found 24 articles (including three trials) from 12 coun-
tries. The limited available data suggests that compared to
passive case finding, TB screening may be associated with less
severe disease; decreased time to diagnosis/first contact with
health services; decreased deaths (among risk groups alone);
decreased patient costs; and higher pre-treatment losses to fol-
low-up. There was no difference in treatment success between
screened and passive case finding groups.
Implications of all the available evidence
With World Health Organization targets to END-TB calling for
decreases in TB deaths, incidence and catastrophic costs, coun-
tries have renewed their interest in TB screening, to find, test
and treat “the missing millions”. We found very limited data
on the individual effects of TB screening. Routine/research
programme implementation must be combined with rigorous
data collection and analysis of critical patient outcomes that
allows the benefits and harms of TB screening to be
characterised.
2 L. Telisinghe et al. / EClinicalMedicine 40 (2021) 101127based TB screening in specific high-risk populations, such as peo-
ple living with HIV/AIDS. But these measures alone do not identify
the substantial burden of undiagnosed TB in these settings, or
effectively reach the poor and vulnerable who face barriers to
seeking health care [3-5]. In 2019, »3 million TB patients were
either not diagnosed or not notified [1]. If untreated, TB is associ-
ated with high mortality and morbidity [6]. Therefore, closing the
case-detection gap by improving access to TB diagnosis and treat-
ment is a priority.
One strategy to address this is TB screening, which encompasses a
wide range of activities aimed at detecting and treating TB patients
earlier in their clinical course [4 ,5]. This should improve the individ-
ual’s clinical outcomes, [4,5] a requirement for traditional screening
programmes [7]. While infectious diseases screening can have both
individual and population effects, [4] understanding whether screen-
ing benefits the individual is critical when considering if to screen.
The costs borne by people seeking TB services and their households
(patient costs) can be high, hindering diagnosis and treatment [8].
Such costs can exacerbate poverty, increasing the vulnerability of
individuals, with further social and health consequences [9,10]. TB
screening, by helping individuals navigate the TB care pathway, may
also potentially decrease patient costs.
But evidence that TB screening improves clinical outcomes and
reduces patient costs is lacking [4,11]. Therefore, we undertook two
systematic reviews to determine if TB screening 1) identifies TB
patients earlier in their clinical course; improves linkage-to-care;improves treatment outcomes; and decreases deaths (clinical review)
and 2) decreases patient costs (economic review).
2. Methods
We undertook two systematic reviews to identify studies reporting
the effect of TB screening on clinical outcomes and patient costs. These
were conducted to inform World Health Organization (WHO) TB
screening guideline development. The Population, Intervention, Com-
parison(s) and Outcomes were determined in collaboration with the
guideline development group (GDG), consisting of a panel of experts in
the field of TB. Themethods followed standard procedures for undertak-
ing systematic reviews [12] and grading evidence quality [13].
2.1. Study populations, interventions, outcomes and definitions
Studies conducted in any population group were considered.
Screening was defined as any provider-initiated intervention includ-
ing 1) using health information/education to encourage appropriate
health-seeking behaviours, with or without increasing access to diag-
nostic services (enhanced case-finding [ECF]); and 2) systematic
screening using any test/procedure (active case-finding in communi-
ties [ACF] and case-finding in health facilities). PCF, the comparator,
was defined as the routine diagnosis of symptomatic TB patients self-
presenting to health services.
We included 23 clinical outcome indicators (Table 1) for earlier
diagnosis (e.g. smear grade, body mass index), linkage-to-care (e.g.
pre-treatment loss to follow-up [LTFU]), treatment outcome (e.g. suc-
cess) and death (e.g. case fatality, mortality). These outcomes were all
rated as critical or very important by the GDG. Clinical outcomes were
assessed among bacteriologically-confirmed TB patients (culture,
Xpert MTB/RIF or smear positive). Treatment success was defined as
cured and treatment completed (without microbiological evidence of
cure) [14]. Pre-treatment LTFU was defined as LTFU between diagnosis
and treatment start. Patient cost input data (Table 1) were broadly cat-
egorised as direct medical (e.g. hospitalisation costs), direct non-medi-
cal (e.g. transportation) and indirect (e.g. lost productivity). Patient
costs were assessed among all TB patients (bacteriologically-confirmed
and clinically diagnosed). Catastrophic cost was defined as total costs
for seeking TB care>20% of the annual household income [1].
2.2. Search strategy
Clinical review: we updated the systematic review conducted by
Kranzer 2013, [11] which covered the period 1/1/1980-13/10/2010
(Figure 1). Articles addressing the research questions from the Kranzer
2013 review were also included in our review. Our update used the
same methods as Kranzer 2013; the search was nested within a sys-
tematic review to determine the number needed to screen to detect a
TB patient in any population [15]. For the number needed to screen
review, Pubmed, EMBASE, Scopus and the Cochrane Library were
searched from 1/11/2010-13/4/2020. Subject headings and key words
covered the concepts of TB and screening (Appendix 1). The title and
abstract screens were broad; articles needed to be original research on
TB screening. Full text screens determined eligibility. Articles from the
number needed to screen review reporting on screening for all forms
of TB were assessed for eligibility for our review.
Economic review: Medline, EMBASE, Scopus and the Cochrane
Library were searched from 1/1/2010-14/8/2020. Subject headings
and key words covered the concepts of 1) TB; 2) screening; and 3)
economic evaluations or economic/financial analysis (Appendix 1).
The Global Health Cost Consortium Unit Cost Study Repository was
also searched for additional articles [16].
For both reviews, bibliographies of identified studies were
searched, and authors contacted for additional data if needed.
Table 1
Clinical outcomes and patient costs* for the clinical and economic review
Clinical outcomes for clinical review
Outcome category Outcome indicator
Sought Identified
Earlier diagnosis Disease severity at diagnosis - microbiology smear positivity among bacterio-
logically-confirmed TB patients;
smear grade; Xpert cycle
threshold values; culture grade/
colonies; time to culture
positivity
smear positivity among bacterio-
logically-confirmed TB patients;
smear grade
Disease severity at diagnosis - radiology CXR severity score/grading -
Disease severity at diagnosis - anthropometric body mass index -
Earlier diagnosis and
linkage to care
Time to first contact with health services duration from start of symptoms
to first contact with health
services
duration from start of symptoms
to first contact with health
services
Time to diagnosis duration from start of symptoms
to diagnosis
duration from start of symptoms
to diagnosis
Time to treatment start duration from start of symptoms
to treatment start; time
between diagnosis and treat-
ment start
duration from start of symptoms
to treatment start; time
between diagnosis and treat-
ment start
Pre-treatment loss to follow-up lost to follow-up between diagno-
sis and treatment start
lost to follow-up between diagno-
sis and treatment start
Treatment Treatment outcomes at treatment end treatment success (cure and com-
pletion); lost to follow-up
treatment success (cure and com-
pletion); lost to follow-up
Disease outcome at treatment end - morbidity body mass index; lung function
test results; TB recurrence
-
Deaths Mortality among screened and unscreened groups all-cause mortality; TB-specific
mortality
all-cause mortality
Case fatality among diagnosed TB patients all-cause case fatality; TB-specific
case fatality
-
Case fatality among treated TB patients all-cause case fatality; TB-specific
case fatality
all-cause case fatality; TB-specific
case fatality
Patient costs* for economic review
Outcome category Outcome - cost input
Pre-diagnosis Costs before TB diagnosis Direct medical - consultation/administration fees; drugs (TB, other); hos-
pitalisation; laboratory investigations, radiology investigations, other
investigations
Direct non-medical costs - transport, food, accommodation, nutritional
supplements, childcare
Indirect - productivity loss
Diagnosis Costs during TB diagnosis
Pre-treatment Costs before TB treatment
May include pre-diagnosis and diagnosis costs
Treatment Costs during TB treatment
Entire illness period Costs during the illness period reported in the study
Catastrophic cost Prevalence proportion of total cost for TB care >20% of annual household income
*costs incurred by TB patients and their households
L. Telisinghe et al. / EClinicalMedicine 40 (2021) 101127 32.3. Eligibility criteria
Only articles in English, French and Spanish were included. Both
(quasi-)randomised controlled trials (RCTs) and observational studies
with screened and PCF groups were eligible. Studies comparing two
different screening strategies or where screening and PCF occurred in
different populations (e.g. screened miners and PCF in the general
population) were excluded. Observational studies not disaggregating
data by screened and PCF groups were excluded. RCTs (individual
and cluster [CRTs]) comparing treatment, death and cost outcomes
by randomised arm were eligible, as this design can mitigate biases
inherent in observational screening studies. For the clinical review,
household contact screening studies where index cases formed the
PCF group and household contacts the screened group were excluded
as individuals from the same households are clustered.2.4. Study selection, data extraction and risk of bias assessment
Study selection, data extraction and risk of bias assessments were
undertaken by two independent reviewers (LT, MR, MAS, MH and CD
conducted the clinical review and LM, and EK conducted the eco-
nomic review). Disagreements were resolved through discussion or,
if required, consultation with a third reviewer.For the clinical review, abstracts of articles were searched to
shortlist studies with a control population (parallel or before-after
design). For the economic review, articles were initially shortlisted
based on the title and abstract. For both reviews, inclusion was based
on full text review of shortlisted articles.
Data were extracted into case report forms. Variables extracted
included study design, population, calendar period, screening strat-
egy, PCF algorithm, TB case definition, participant numbers and out-
come data. Methodological quality of cross-sectional studies was
assessed across four domains; valid participant selection, valid expo-
sure ascertainment, valid outcome ascertainment, and adequate con-
trol for confounders [13]. Quality assessment of CRTs was undertaken
using the Cochrane Risk of Bias tool [17,18]. For economic studies the
Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) statement was used [19].
2.5. Data synthesis and analysis
Due to the heterogeneity of included studies (populations, screen-
ing tools, effect estimates, etc), data synthesis for both reviews was
narrative. For treatment success and on-treatment case fatality calcu-
lations, we only included cured, treatment completed, death, treat-
ment failure, LTFU, and not evaluated (including transferred out) in
the denominator; other outcomes reported, such as still on
Figure 1. Study selection process - flow diagram of number of original research articles considered for the clinical review.
The clinical review was nested within a systematic review to determine the number needed to screen to detect a TB patient in any population. *represents the study selection
process for the number needed to screen review.
yThe starting point of the clinical review, which is reported in this manuscript.
{Previous systematic review by Kranzer et al 2013, authors and bibliography searches.
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Table 2
Characteristics of studies included in the clinical review (N=18) and economic review (N=6)
First author and
Location
Population Study years Screening: strategy and tools TB case definition Sample/cohort* Outcomes OR Details of costing studies
and costs collected
Screen PCF
Clinical review – general population observational studies
Abdurrahman 2016
Abuja, Nigeria
Urban including slums 2010-2014 ACF: One off community health worker house-to-house




485 209 Smear grade




2 suburbs 2002-2005 Prevalence survey: sputum smear and culture for all col-









Rural 1 district 2003 Prevalence survey: symptoms and/or on TB treatment. Spu-
tum collected for smear if +.
Smear +Adult ≥15
years




Rural and urban 1 sub-
district
2001-2003 Prevalence survey: CXR and symptoms. Sputum collected
for smear and culture if symptoms or abnormal CXR.
Smear +Adult ≥15
years




Rural and urban 1 sub-
district
1998-2001 Prevalence survey: CXR and symptoms. Sputum collected
for smear and culture if symptoms or abnormal CXR.
Smear +Adult ≥15
years




Rural and urban 1 sub-
district
1999-2000 Prevalence survey: CXR and symptoms. Sputum collected
for smear and culture if symptoms or abnormal CXR.
Smear + 96 330 Smear grade





Rural 8 districts 1990-1993 Likely ECF (unclear): outreach TB camps (diagnostic serv-
ices) lasting 2-4 days with pre-camp publicity in areas
away from health posts, with high TB burden or where
community requested services. If symptomatic sputum
collected at camps. 45 camps over 3 years.
Smear +New TB 68 1306 Treatment outcomes
Cassels1982
East Nepal
Rural 1 district 1978-1980 ACF: one-off house-to-house symptom screen by vaccina-
tors. Pots left for sputum collection if symptoms, with
drop-off at designated centres within 20 minutes walking
distance.
Smear + 111 159 Treatment outcomes




Rural 2 districts 2003-2004 ECF: x1/month for 12 months IEC activities by community
promoters¶ encouraging those with symptoms to attend
monthly diagnostic outreach clinic where sputum col-
lected for smear.
Smear + 159 221 Treatment outcomes
Clinical review – risk groups observational studies
Shewade 2019ʃ




2016-2017 ACF: one-off community volunteer house-to-house symp-
tom screen. Referral for sputum smear if symptoms.
Smear +Adult ≥15
years
275 297 Smear grade
Treatment outcomes
Shewade 2019ʃ




2016-2017 ACF: one-off community volunteer house-to-house symp-
tom screen. Referral for sputum smear if symptoms.
Smear +Adult ≥15
years
234 231 Duration of symptoms to 1) first contact
with health services; 2) diagnosis
Time between diagnosis and treat-
ment start
Time between symptoms and treat-
ment start
Paiao 2016
Mato Grosso do Sul
state, Brazil
Prisoners in 12 prisons 2013-2014 ACF: x2 symptom screen (at baseline and 1 year later). Spu-
tum collected if symptoms.
Culture + Adult ≥18
years







2005-2010 ACF: mobile CXR screening programme. Screening in com-
munity settings where hard to reach people can be
accessed (e.g. hostels, day centres, drug treatment serv-
ices, prisons).




Migrants 1993-1998 ACF: entry and every 6 months for 2 years CXR screening
programme. Sputum for smear and culture if abnormal
CXR.
Smear or culture + Stay
<30 months
454 368 Smear positivity of culture confirmed
TB patients
Symptom duration at diagnosis
Treatment outcomes


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































smear + TB patients
2014 ACF: all household and symptomatic neighbourhood con-
tacts invited for CXR screening on a specific date. Sputum
for Xpert if abnormal CXR or symptoms.
New PTB with cured or
completed treatment
outcome
108 100 Empirical; CA from patient perspective;
Primary costing data; 2014 cost ref-
erence year
Pre-treatment costs: Direct medical –
administration, tests, x-ray, drugs,
hospitalisation; Direct non-medical –
transport, food, guardian, insurance
reimbursement; Indirect – lost
income from health seeking and sick
leave
Treatment costs: Direct medical –hos-
pitalisation; Direct non-medical –
transport (DOTS, drug pick-up, fol-
low-up visits), supplemental food,
guardian/care giver, interest for bor-
rowed money, insurance re-imburse-
ment; Indirect – lost income (patient,
guardian/care giver), reduced house-






2012 Prevalence survey: house-to-house symptom screen. Spu-
tum collection if symptoms for smear/culture.
Adult ≥15 years on at
least 2 weeks of TB
treatment
103 Decision modelling; CEA from societal
perspective; Primary and secondary
costing data; 2013 cost reference
year
Diagnosis costs: Direct non-medical -
transportation, food, care giver, child
care/hired help; Indirect – patient and
care giver time lost
* number of people with TB unless otherwise indicated; PCF=passive case-finding; ACF=active case-finding; + = positive; CXR=chest radiograph; ECF=enhanced case finding; IEC=information, education and communication
¶ community-promoters - individuals with previous experience in community outreach activities who are provided training about TB).
Ŧ includes slums, tribal areas, scheduled caste communities, areas where occupational lung diseases is high, areas where individuals with high risk of acquiring TB reside including stone crushing/mining/weaving industry/
unorganized labour (construction workers etc)/homeless, high HIV/AIDS burden areas, areas or communities with high TB incidence (including prisons) and among household contacts of sputum smear positive TB patients.
ʃ Papers report different outcomes on the same study participants; BCG=Bacillus Calmette–Guérin; n/a=not applicable.
† total number in screened and passive case-finding group; CA=cost analysis; OPD=outpatient department; PTB=pulmonary TB; x-ray=radiography; HCW=health care worker; CEA=cost effectiveness analysis; DOTS=Dir-








8 L. Telisinghe et al. / EClinicalMedicine 40 (2021) 101127treatment, were excluded. Smear grade was recategorized, with
grades scanty/1+/2+ combined to reflect lower grades (and less
extensive disease) and 3+ reflecting higher grades (and more exten-
sive disease). A sensitivity analysis was conducted recategorizing
smear grades scanty/1+ as lower grade and 2+/3+ as higher grade.
Where proportions were reported, 95% confidence intervals (95%CI)
were calculated using Stata version 15 (StataCorp).
2.6. Role of the funding source
The WHO commissioned this work to inform TB screening guide-
line development. The WHO had no role in the conduct of the study
or writing the report. The corresponding and last author had access




From 27,270 articles, 18 were eligible [20-37] (Figure 1 and
Table 2); seven were not reported in the previous review [20,29-
32,36,37]. We only identified n=12/23 (52%) of the outcome indica-
tors sought (Table 1); no studies reported on the remainder. All stud-
ies reported on smear and/or culture positive TB (Table 2); no studies
reported on Xpert MTB/RIF positive TB.
Fifteen were observational studies. The characteristics of TB
patients identified through screening and PCF varied across these
studies (Tables 3-5). All had a high risk of bias for the outcomes iden-
tified (Appendix 2); most (n=11/15) did not adjust for potential con-
founders.
3.2. General populations
Eight observational studies were conducted in rural and/or urban
populations; all were from South Asia and sub-Saharan Africa [20-
27]. Most (n=7/8) involved one-off house-to-house ACF strategies
(n=5/7 were prevalence surveys) [20-25,27]. Four (50%) used symp-
tom screening, [20,22,26,27] three (38%) chest radiographs (CXRs)
and symptoms, [23-25] and one (12%) prevalence survey conducted
sputum smear and culture on all individuals [21].
Three studies [20,21,25] reported on smear grade (Table 3 show-
ing proportions and prevalence ratios and Appendix 3). All showed
screened TB patients were less likely to have higher smear grades,
but the small sample size of the screened group gave wide CIs in one
[21]. Two studies conducted in the same south Indian population
over consecutive calendar periods reported on pre-treatment LTFU
(Table 4) [23,24]. In both, the proportion LTFU among those screened
was higher (screened 23% and 29% versus PCF 15% and 14%). Among
individuals LTFU, none died in the screened group, while nearly 20%
had died in the PCF group for whom outcomes were available [23].
Symptom duration was longer in the PCF group in one study (cough
<3 weeks 13% in PCF versus 28% in screened group) [25] but shorter
in another (mean cough duration 6.8 weeks in PCF versus 10.3 weeks
in screened group) [20]. One study found no difference in time to
treatment start between screened and PCF groups [22].
Four studies involving different screening strategies (symptom;
CXR; and smear/culture screening) reported on treatment outcomes
(Table 5 showing proportions and prevalence ratios). In three the
proportions with treatment success among screened and PCF groups
was similar, ranging from 68-80% [21,25,26]. Two studies also
reported on pre-treatment LTFU; both only provided data for the
screened group (26-32%) [21,25]. There was no difference in the pro-
portion who died between screened (range 6-8%) and PCF (range 4-
11%) groups in four studies [21,25-27]. There was no difference in theproportion LTFU during TB treatment between screened (range 6-
20%) and PCF (range 8-19%) groups [25,26].
One CRT, conducted in 32 contiguous rural Ethiopian communi-
ties with difficult access to health care, used monthly ECF with out-
reach clinics to initiate diagnosis (continued at health facilities
through routine services) over 1 year in 12 intervention communities
(Table 2, Table 5 and Appendix 2) [28]. There was no difference in TB
patient characteristics, treatment success, on-treatment case fatality
or on-treatment LTFU by study arm. Data on pre-treatment LTFU was
not provided. But pre-treatment symptom duration was significantly
lower in the intervention group (median difference between inter-
vention and control group -47 days; 95%CI -76 to -19; 55-60% reduc-
tion in duration in the last three quarters compared to the first
quarter in intervention communities, with corresponding 3-20% fall
in control communities). Because of insufficient information to assess
one bias domain, the risk of bias assessment raised some concerns.
3.3. Risk groups
Seven observational studies reported on risk groups, including
prisoners,[29-32] migrants, [33] miners, [34] and homeless people.
[32,35]. Four involved established European and South African CXR
screening programmes [32-35]. Three studies from India and Brazil
reported on one-off/limited ACF using symptoms [29-31].
One Indian study found no difference in smear grade among
screened and PCF groups (Table 3 showing proportions and preva-
lence ratios) [29]. Three European and one Brazilian study reported
on smear positivity among culture-confirmed TB patients [31-33,35].
The proportion with positive smears was lower in those screened in
three [31-33]. One study showed no association but small sample
sizes gave wide CIs in both study groups [35]. No studies reported on
pre-treatment LTFU (Table 4). Symptom duration was shorter in the
screened group in two studies (prevalence of diagnosis delay 50
days was 23% lower in the screened group in an Indian study, [30]
and the median symptom duration was 7.5 weeks in the PCF versus
0.0 weeks in the screened group in a study from the Netherlands
[33]. Time to treatment start in one Indian study [30] found no differ-
ence between the screened and PCF groups.
Three studies (including two established CXR screening pro-
grammes) reported on treatment outcomes (Table 5 showing propor-
tions and prevalence ratios). The proportions with treatment success
among screened and PCF groups was similar, ranging from 80-90% in
two [29,33]. In one Indian study reporting on one-off symptom
screening, there was no difference in case fatality among screened
and PCF groups [29]. Two studies reporting on »4-5 years of data
from established CXR screening programmes among migrants to the
Netherlands and South African miners showed higher case fatality
among the PCF group (PCF versus screened odds ratio [OR] 15.3;
95%CI 2.0-118.0; adjusted OR 5.6; 95%CI 2.6-12.2 respectively)
[33,34]. There was no difference in the proportion LTFU during TB
treatment between screened (range 6-10%) and PCF (range 7-10%)
groups [29,33].
Two CRTs were identified (Table 2, Table 5 and Appendix 2)
[36,37]. One among Indian neonates compared fortnightly ACF over 2
years, in 297 intervention communities to PCF in 295 control commu-
nities [36]. Screening was associated with lower all-cause mortality
compared to PCF (adjusted OR 0.68 [95%CI 0.47-0.98]), which was
attributed to decreases in pneumonia/respiratory infections. The risk
of bias was high which could work to underestimate the effect of
screening on mortality. A CRT among Vietnamese household contacts
of TB patients, compared CXR and symptom screening at 0, 6, 12 and
24 months in 36 intervention communities to PCF in 34 control com-
munities [37]. Screening was associated with lower all-cause mortal-
ity compared to PCF (risk ratio 0.60 [95%CI 0.50-0.80]). The risk of
bias assessment raised some concerns as the data represented a post-
hoc analysis.
Table 3
Smear grade 3+ and smear positivity among culture confirmed TB patients reported in n=8 observational studies
First author, country and
population, screening tool
Group Smear grade 3+ /
all smear positives
Smear + / culture confirmed Prevalence
ratio (screen/PCF)
Comments





Screen 101/480 21% (17-25%) - - 0.46 Diagnosed TB patients
Screened vs PCF - screened group more
likely to be older, married and less
likely to be HIV infected.




Screen 6/18 33% (13-59%) - - 0.63 Denominator for smear grade - screened
group includes those lost to follow-up
pre-treatment; PCF those starting
treatment only
Diagnosed in screened and on treat-
ment in PCF groups - no difference in
age and gender.




Screen 3/96 3% (1-9%) - - 0.07 Denominator for smear grade - screened
group includes those lost to follow-up
pre-treatment; PCF those starting
treatment only
All (smear +ve and -ve) diagnosed in
screened and on treatment in PCF
groups - screened group more likely to
be older, male, illiterate, sole earner,
have poor quality house and a 1 room
house





Screen 39/233 17% (12-22%) - - 0.84 On treatment TB patients
Screened vs PCF- screened group more
likely to be older, from rural areas and
live further frommicroscopy units.




Screen - - 4/40 10% (3-24%) 0.20 Diagnosed TB patients






Screen - - 11/23 48% (27-69%) 0.67 On treatment TB patients
Association between screening and
smear positivity maintained after
adjusting for age and gender




Screen - - 60/159 38% (30-46%) 0.68 On treatment TB patients
Screened vs PCF - screen detection var-
ied by country of origin, decreased
with increasing length of stay and was
less likely among illegal migrants.




Screen 11/16 69% (41-89%) 0.87 On treatment TB patients
PCF 15/19 79% (54-94%)
* n/N=number with smear grade 3+/total number with smear grade scanty, 1+, 2+ and 3+.
** n/N=number smear positive/total number culture positive; 95%CI = 95% confidence interval; PCF=passive case-finding.
† included slums, tribal areas, scheduled caste communities, areas where occupational lung diseases is high, areas where individuals with high risk of acquiring TB reside includ-
ing stone crushing/mining/weaving industry/unorganized labour (construction workers etc)/homeless, high HIV/AIDS burden areas, areas or communities with high TB incidence
(including prisons) and among household contacts of sputum smear positive TB patients; CXR=chest radiograph.
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From 2841 articles, six observational studies were eligible [38-43]
(Figure 2 and Table 2); none were included in the previous review.
Most were from South Asia (n=4; 67%), [38-41] with one from South
East Asia, [42] and one from sub-Saharan Africa [43]. Most studies
included general populations (n=4; 67%); [38-40,43] three involved
house-to-house screening [38,39,43]. Risk groups were those with
structural risk factors (n=1), [41] household and neighbourhood con-
tacts (n=1), [42] and social contacts (n=1) [39] of TB patients, and
health facility attendees (n=2) [39,40]. Four studies (67%) used symp-
tom screening alone, [39-41,43] whereas two (33%) used CXR andsymptoms. [38,42]. The analyses undertaken varied; four performed
cost analysis [38,39,41,42] and two conducted cost-effectiveness
analysis [40,43]. All studies reported findings transparently; three
[38-40] met all CHEERS checklist criteria (Appendix 4).
Data were summarised using different measures (means,
medians). The illness periods for which costs were reported varied;
two studies reported diagnosis costs alone, [41,43] two pre-treat-
ment and treatment costs, [39,42] one diagnosis and treatment costs,
[38] and one pre-diagnosis, diagnosis and treatment costs [40]
(Table 2 and 6; Appendix 5). While cost inputs and granularity of
reporting varied across studies, all calculated aggregated costs for the
reported illness period (Table 6 and Appendix 5). In all studies, higher
Table 4












- Screened 243 57 23 18-29 Screened group  no deaths. Reasons for
defaulting included not interested in ini-
tiating treatment, symptoms too mild,
too sick/old and work-related problems.
PCF group  19% died from among those
for whom a default reason was known.





- Screened 231 68 29 24-36
PCF 833 120 14 12-17





Cough <3 weeks Screened 96 27 28 <0.001 Baseline characteristics of all (smear +ve
and -ve) diagnosed in screened and on
treatment in PCF groups - screened group
more likely to be older, male, illiterate,
sole earner, have poor quality house, 1
room house, lower smear grade and new
smear -ve disease.
PCF 272 35 13





Cough duration in weeks Screened 485 10.3 2.4 <0.001 Baseline characteristics of diagnosed TB
patients (screened vs PCF) - screened
group more likely to be older, married
and less likely to be HIV infected.
PCF 209 6.8 2.6






Symptom 90 days Screened 13 6 46 1
Baseline characteristics of on treatment
TB patients (screened vs PCF) - screened
group younger and a higher proportion
were women.
PCF 24 10 42
Risk groups








from sputum eligibley (days)
Screened 225 12 3-31 0.999 Baseline characteristics of on treatment TB
patients (screened vs PCF)- screened
group more likely to be older, from rural
areas, less educated and live further from
microscopy units.
Adjusted analysis showed no association
between patient-level delay and case-
finding, but showed reduction in total
diagnosis delay among those screened
(screened versus PCF linear regression of
log transformed delay in days after
adjusting for confounders and clustering
beta coefficient -0.31; 95%CI -0.62 to
0.00; p=0.052; screened versus PCF
adjusted prevalence ratio for delay 50
days 0.77; 95%CI 0.63-0.94; p=0.009)
PCF 230 10 3-43
Health system diagnosis delayT̵ (days) Screened 229 5 0-61 0.008
PCF 229 19 1-76
Total diagnosis delay{ (days) Screened 229 45 18-106 0.131







Symptom duration in weeks
among those reporting
symptoms
Screened 142 0.0 - <0.001ʃ Baseline characteristics of on treatment TB
patients (screened vs PCF) - screen detec-
tion varied by country of origin,
decreased with increasing length of stay
and was less likely among illegal
migrants.
PCF 332 7.5 -







Total treatment delay from
sputum eligibleï (days)
Screened 227 52 22-112 0.37 Baseline characteristics of on treatment TB
patients (screened vs PCF)- screened
group more likely to be older, from rural
areas, less educated and live further from
microscopy units.
Adjusted analysis showed no association
with case-finding (screened versus PCF
linear regression of log transformed
delay in days after adjusting for con-
founders and clustering beta coefficient
-0.20; 95%CI -0.50 to 0.10; p=0.181).
PCF 229 62 23-128
LTFU=loss to follow-up; pre-treatment LTFU=default between diagnosis and treatment start; N=total number of people with TB; n=number with outcomes; %=proportion;
95%CI=95% confidence interval; CXR=chest radiograph; +ve=positive; PCF=passive case-finding; -ve=negative; IQR=interquartile range; SD=standard deviation; ΔOther symptom
(fever, weight loss, chest pain and anorexia) durations to diagnosis were assessed, only weight loss was significantly higher in the screened population compared to passively found
TB patients;*included slums, tribal areas, scheduled caste communities, areas where occupational lung diseases is high, areas where individuals with high risk of acquiring TB reside
including stone crushing/mining/weaving industry/unorganized labour (construction workers etc)/homeless, high HIV/AIDS burden areas, areas or communities with high TB inci-
dence (including prisons) and among household contacts of sputum smear positive TB patients; ypatient diagnosis delay=from sputum eligible (15th day of continuous cough/fever
or day of the first episode of haemoptysis) to first visit to health care provider.
T̵ health system diagnosis delay=from first visit to health care provider to date of diagnosis; {total diagnosis delay=from eligible for sputum examination to diagnosis; ʃsimilar dif-
ference observed when results were restricted to n=99 with smear positive disease; ïtotal treatment delay= from sputum eligible (15th day of continuous cough/fever or day of the
first episode of haemoptysis) to treatment start.
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Table 5
On-treatment outcomes (treatment success, case fatality and default on-treatment) among smear, Xpert and/or culture positive TB patients reported in n=7 observational studies and n=1 CRT, and, all-cause mortality reported in n=2
CRT
Observational studies
First author, country and
population, screening tool
Group Treatment success PR Case fatality PR LTFU on treatment Pre-treatment LTFU* Comments





Screen 16/20 80% (56-94%) 1.00 2/27 7% (1-24%) 1.95 - - 7/27 26% Denominator for case fatality - screened group includes those LTFU pre-
treatment; PCF those starting treatment only.
Baseline characteristics of diagnosed in screened and on treatment in
PCF groups - no difference in age, gender, smear grade between
groups.




Screen 45/65 69% (57-80%) 1.01 4/65 6% (2-15%) 0.88 13/65 20% (11-32%) 31/96 32% Baseline characteristics of all (smear +ve and -ve) diagnosed in screened
and on treatment in PCF groups - screened group more likely to be
older, male, illiterate, sole earner, have poor quality house, 1 room
house, lower smear grade and new smear -ve disease.




Screen 50/64 78% (66-87%) 1.00 5/64 8% (3-17%) 0.96 4/64 6% (2-15%) - - Baseline characteristics of diagnosed TB patients (screened vs PCF) –
screened more likely to be female (and age among women tended to
be older).




Screen - - 9/111 8% (4-15%) 0.76 - - 11/111 10% Denominator for case fatality - screened group includes those LTFU pre-
treatment; PCF group are those starting treatment. Baseline charac-
teristics of diagnosed TB patients (screened vs PCF) – screened group
were older and the male to female ratio was lower.






Screen 247/274 90% (86-93%) 1.03 7/274 3% (1-5%) 0.69 16/274 6% (3-9%) - - Baseline characteristics of on treatment TB patients (screened vs PCF)-
screened group more likely to be older, from rural areas and live fur-
ther frommicroscopy units.
No association between screening and treatment success after adjust-
ing for age, gender and distance from microscopy unit.




Screen 384/454 85% (81-88%) 1.06 1/454 0.2% (0-1%) 0.07 47/454 10% (8-14%) - - Baseline characteristics of on treatment TB patients (screened vs PCF) -
screen detection varied by country of origin, decreased with increas-
ing length of stay and was less likely among illegal migrants.




Screen - - 12/1225 1% (0.5-2%) 0.14 - - - - Baseline characteristics of on treatment TB patients (screened vs PCF) -
screened less likely to be HIV infected.
After adjusting for HIV status, sputum status, treatment category, age,
disease extent on CXR, silicosis and drug resistance, association
between PCF and case fatality maintained (PCF versus screened aOR
5.6; 95%CI 2.6-12.2)











87 contiguous administrative units clustered into 32 communities
32 communities randomised – 12 to screening and 20 to PCF
NŦ smear +ve TB patients - screen=159; PCF=221
Follow-up during treatment




n=128 (81%) vs n=165 (75%); difference (95%CI) 6 (-4 to 15); p=0.12
Death: screen vs PCF n=5 (3.1%) vs n=7 (3.2%); difference (95%CI) -0.1 (-4 to 4); p=0.49
LTFU on treatment:
screen vs PCF





Cluster – villages or subsection of towns
592 clusters randomised (8 strata) – 297 to screening and 295 to PCF
NŦ in each group - screen=2215; PCF=2167
Follow-up 2 years
All-cause mortality: screen vs PCF n=49 (2.2%) vs n=71 (3.3%); aOR¶ (95%CI) 0.68 (0.47-0.98)













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































12 L. Telisinghe et al. / EClinicalMedicine 40 (2021) 101127total costs were incurred in the PCF compared to screened group.
Four studies assessed catastrophic cost prevalence, which was higher
in the PCF (range 12-61%) compared to screened (range 9-45%) group
[38,39,41,42]. In two Indian studies, using house-to-house screening
among general populations [38] and those with structural risk fac-
tors, [41] total costs and catastrophic costs (on multivariable analysis)
were significantly lower in the screened compared to PCF groups. In
two studies with small sample sizes, among Cambodian household
and neighbourhood contacts of TB patients [42] and among mainly
outpatient attendees and social contacts of TB patients in Nepal, [39]
there was no statistically significant difference in total costs and cata-
strophic costs on univariable analysis between screened and PCF
groups. Two studies did not assess differences in mean total costs or
report catastrophic costs [40,43].
4. Discussion
We synthesised literature published between 1980-2020, to gen-
erate up-to-date evidence for the individual effects of TB screening.
We found very few studies addressing the review questions. The
WHO END-TB strategy sets out ambitious targets to reduce TB death,
incidence and catastrophic costs by 2035 [44]. At the 2018 United
Nations General Assembly high-level meeting, world leaders reaf-
firmed their commitment to ending TB [45,46]. At a time of unprece-
dented political commitment to find, test and treat TB patients,
evidence for strategies such as TB screening to inform in-country
decision making globally, is vital. Further, the reversal in TB control
efforts and case-detection due to the COVID-19 pandemic [47,48]
may going forward, make TB screening even more important.
A general challenge with interpreting the findings is the observa-
tional design of most studies. This is compounded by differences in
reported outcome measures, insufficient data on the care cascade,
unadjusted analyses, small sample sizes, and length-time bias (where
screening may detect individuals with less severe indolent disease
who may have different characteristics, longer disease course and
better outcomes including survival, than those who are identified
through PCF). These limitations must be kept in mind when inter-
preting results. Definitive evidence for the effects of TB screening
requires well-conducted RCTs. However, these require large sample
sizes, long term follow-up and are resource intensive. We only identi-
fied three RCTs, conducted over relatively short time-periods (1-2
years) [28,36,37]. Therefore, insights from routine programme imple-
mentation are essential. While overall screening approaches will
depend on the context and available resources, general principles
dictate that screening is not one-off, is integrated into health systems,
with quality-assured diagnosis and treatment services [4,7]. We only
identified four studies (all in risk groups) reporting on established
screening programmes [32-35]. But there was general consistency in
most findings, irrespective of the screening strategy used.
TB screening, by engaging individuals earlier into care, should
result in earlier diagnosis when disease is less severe [4]. Smear grade
and proportion smear positive among culture-confirmed TB patients
was lower in the screened group in most studies with larger sample
sizes, suggesting screening does identify individuals with less severe
disease. Length-time bias may explain this. But the reported reduc-
tion in pre-diagnosis symptom duration among those screened, while
subject to recall bias, suggests earlier diagnosis plays a role. If individ-
uals are identified earlier, when disease is less severe, and linked to
care, this should translate to better outcomes for the individual [4].
Studies consistently showed no difference in treatment success
between screened and PCF groups. This could be a true finding
(screening does not improve treatment success). Or it may be due to
potential confounders or the inherent limitations of routine data,
where identifying TB patients screened from those self-presenting
can be challenging and successful outcomes may be over-ascertained,
potentially biasing the effect towards the null. Data on pre-treatment
Table 6
Costs for the entirety of the illness period and the prevalence of catastrophic costs from n=6 studies reporting on patient costs*
First author, population and
screening method, illness period and
costs reported
Combined cost for the illness period (US$) Catastrophic cost prevalence Comments
Screen PCF p-value Screen PCF p-value
Muniyandi (2020); India
General population; symptoms and
CXR screen
Diagnosis and treatment








0.001 9% 29% - Screened group more likely to be older, illit-
erate, smoke and report no symptoms. No
data on bacteriological status.
On adjusted analysis catastrophic costs were
significantly higher among the PCF group
(aOR 3.68; 95%CI 1.62-8.33)
Gurung (2019); Nepal
OPD attendees, social contacts of
people with TB, general population
TB camps; symptom screen
Pre-treatment (from symptom
start) and intensive treatment
phase






0.16 45% 61% 0.14 60% OPD; 34% social contacts; 6% camps
No difference in socio-demographic, disease
and health seeking characteristics
between groups.
PCF group interviewed >1 month after
treatment start (∼70%) reported lower
costs than those interviewed within 1





From sputum eligible¶ to diagnosis






<0.001 10% 12% - Screened group more likely to be older, from
rural residence, have no formal education,
have lower median monthly income and
not report weight loss. No significant dif-
ference in smear grade, weight in Kg, hae-
moptysis or fever between screened and
PCF group
On adjusted analysis catastrophic costs were
significantly lower among the screened
group (aPR 0.68; 95%CI 0.69-0.97)
Morishita (2016); Cambodia
HH and neighbourhood contacts;
CXR screen
Pre-treatment and during 6 months
of treatment






0.10 36% 45% 0.24 No difference in socio-demographic charac-
teristics.
PCF group more likely to be smear/Xpert
positive and live near health centres. No
other clinical data provided
Hussain (2019); Pakistan
HCW - incentives; clinic attendees
– symptom screen; general popula-
tion – TB IEC
Pre-diagnosis, diagnosis and treat-
ment phase
Direct (medical, non-medical) and
indirect costs
Mean† 59 71 NR NR 52% smear negative in screened group and












* All values (costs and proportions) rounded to the nearest whole number; PCF=passive case-finding; CXR=chest radiograph; SEM=standard error of the mean; aOR=adjusted odds
ratio; 95%CI=95% confidence interval; OPD=outpatient department; IQR=interquartile range
** included slums, tribal areas, scheduled caste communities, areas where occupational lung diseases is high, areas where individuals with high risk of acquiring TB reside includ-
ing stone crushing/mining/weaving industry/unorganized labour (construction workers etc)/homeless, high HIV/AIDS burden areas, areas or communities with high TB incidence
(including prisons) and among household contacts of sputum smear positive TB patients
¶ from 15th day of continuous cough, fever or the day of the 1st episode of haemoptysis; aPR=adjusted prevalence ratio; HH=household; HCWs=health care workers; IEC=informa-
tion, education and communication
† no measure of spread reported; NR=not reported
L. Telisinghe et al. / EClinicalMedicine 40 (2021) 101127 13LTFU, while limited and not generalisable, suggests pre-treatment
LTFU is high among screened TB patients; in one study, no deaths
were reported in the screened group [23]. In the PCF group, there
was high pre-treatment case fatality, [23] similar to other reports
[49]. Therefore, on-treatment outcomes, which ignore deaths pre-
treatment, may underestimate the effects of screening.
Two studies (Churchyard 2000 and Verver 2001) found screening
was associated with lower case fatality, [33,34] but due to their
observational nature we cannot exclude length-time bias and uncon-
trolled confounders. Both report on established CXR screening pro-
grammes, with large sample sizes, access to good health systems and
better reporting of deaths. While neither study report on pre-treatment LTFU, individuals treated could be more representative of
those diagnosed. Churchyard 2000, among miners did not report
treatment success by screened and PCF groups [34]. Verver 2001,
showed no difference in treatment success, [33] but this study among
migrants, had few deaths overall which may reflect a healthy migrant
effect, giving better overall outcomes across study groups. Two CRTs
(Jenum 2018 in neonates and Fox 2018 in household contacts of TB
patients) found screening was associated with lower all-cause mor-
tality, [36,37] with Fox 2018, showing no difference in on-treatment
outcomes (among all TB patients) between study groups [37]. The
limitations of these CRTs (generalisability, post-hoc analysis) need to
be borne in mind when interpreting findings. But, in line with these
Figure 2. Study selection process - flow diagram of number of original research articles considered for the economic review
14 L. Telisinghe et al. / EClinicalMedicine 40 (2021) 101127are RCTs comparing different screening strategies in risk groups,
showing lower mortality/case fatality among individuals, especially
with severe disease, receiving more intensive screening [50,51]. As
all data represent risk groups, findings cannot be extrapolated to gen-
eral populations.
Pre-treatment LTFU, while likely to be setting-specific, can be fre-
quent with interventions targeting “well” individuals. Programmes
should ensure that all individuals diagnosed are linked to treatment,
with context-specific barriers to engaging with care identified and
mitigated. A CRT in rural Ethiopia where health care access is difficult,
compared ECF to ECF plus community-based care (sputum collection,
providing treatment and supporting adherence) by community
health workers over one year [52]. Treatment success was signifi-
cantly higher in the latter group, highlighting how combining screen-
ing with strategies that minimise pre-treatment LTFU can increase
treatment success. Further, if all individuals diagnosed at an earlier
stage are not started on treatment, reducing transmission, popula-
tion-level benefits [4] shown in trials [53,54] may not be realised.
Due to the limitations of the identified economic studies (e.g. dif-
ferences in the cost inputs and illness periods; small sample sizes;
recall bias; and unadjusted analyses) we cannot directly compare
findings between studies. Further, the data are mostly from South
Asia, limiting generalisability. Nevertheless, all studies consistently
showed lower total costs and catastrophic cost prevalence among
those screened. While we did not assess screening costs/cost-effec-
tiveness from a health system perspective, this can be high. When
viewed from a societal perspective, there may be potential offsets to
these costs. But, given the limitations of the included studies, only
cautious conclusions can be drawn. Patient costs are often reported
as barriers to accessing TB care.8,55-57 Therefore, standardising thecollection and reporting of patient cost inputs as part of routine pro-
gramme monitoring could help identify how interventions affect this
patient important outcome, guiding policy making.
These reviews have several limitations. We only searched four
databases; the grey literature was not searched. Only English, French
and Spanish articles were included. The economic review only
included articles from 2010. Therefore, some relevant articles may
have been missed. As studies were heterogeneous, we could not
meta-analyse the data. We did not assess publication bias.
An important finding was the limited data on individual outcomes,
despite many publications on TB screening studies/programmes [58].
Going forward, studies/programmes must prioritise reporting this
data, along with the screening cascade. Evaluations should be carefully
designed, to identify appropriate control groups and adjust for poten-
tial confounders, allowing valid comparisons across diagnosed TB
patients in screened and unscreened populations.
In conclusion, we found very limited data on the effect of TB
screening on individual outcomes. Routine/research programmes
must prioritise collecting and reporting this data.
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